ClinicalTrials.gg
No longer availableNCT03460782Updated Nov 8, 2019

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

An expanded access record providing Ipilimumab in Glioblastoma and Glioma of Brain, sponsored by Center Trials & Treatment. No longer available at 11 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-11-08.

Sponsored by Center Trials & Treatment · Expanded access

Study type
Expanded access
Access type
Individual patients
Ages
18 Years to 80 Years
Sex
All
01

Study summary

IPILIMUMAB Extended Access Program for patients who received chemotherapy and / or radiation therapy before the protocol, before or after the operation.

Read the detailed description

It is not yet known which protocols are a better treatment for glioblastoma or glioma.

The ipilimumab extended-access program for patients who received previous chemotherapy and / or radiation therapy by protocol, before ((for non-operable cases) or after the operation.

Monoclonal antibodies of CTLA-4, such as ipilimumab, may block tumor growth in different ways by targeting certain cells and activating the patient's immune system to fight the disease.

02

Conditions studied

  • Glioblastoma
  • Glioma of Brain

Keywords

  • Ipilimumab
  • Glioblastoma
  • Glioma
03

In context

Glioblastoma

2,132 studies on the registry are indexed under Glioblastoma; 464 are open to participants now.

Browse Glioblastoma studies →

Lead sponsor

Center Trials & Treatment is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Glioblastoma.
  • Glioma Brain.
  • Male or female subjects aged ≥18 years.
  • Histopathological evidence of glioblastoma or glioma.
  • Patients still alive must provide if required by local regulations
  • Maximal tumor diameter (including residual tumor and resection cavity if subjects had tumor resection rather than only stereotactic ) up to 7cm or less.
  • performance status (Appendix 2) of ≥60.
  • Availability of a paraffin-embedded or frozen tumor-tissue block with a minimum of 0.5 cm2 and 5 unstained slides from the glioblastoma or glioma tissue specimen.
  • Not earlier than 35 days after surgery.
  • An interval of at least 2 week for stereotactic biopsy from the start of study treatment.
  • A contrast-enhanced MRI must be obtained within 7 days of the first dose of study treatment.
  • Adequate hematologic, hepatic, and renal function defined by test
  • Women must have a negative serum or urine pregnancy test before 24 hours of initiation of study drug.
  • Any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not . Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL to be defined as post-menopausal.

Women receiving ipilimumab will be instructed to adhere to for a period of 35 weeks after the last dose of program.

  • Men receiving ipilimumab and who are sexually active will be instructed to adhere to contraception for a period of 39 weeks after the last dose of program.
  • Contraception is not required for men with documented vasectomy.
  • Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
  • Women must not be breastfeeding.
  • Willing to and capable of providing written informed consent prior to any program related procedures.
  • Ability and willingness to comply scheduled visits, treatment plans, laboratory tests, and other program-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Prior systemic treatment antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.
  • Planned participation in another study intended for therapy of glioma or glioblastoma.
  • Primary brainstem or spinal cord tumor.
  • Diffuse gliomatosis.
  • Сonfirmed mutation of the IDH1/2 genes.
  • Stem or dendritic cell therapy 60 days before the program or 45 days after the last infusion of ipilimumab.
  • Systemic treatment with either doses of (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 21 days of study drug administration.
  • Patients on a standard high-dose steroid taper after craniotomy or stereotactic may have received a higher dose of corticosteroids within 21 days of registration, however must be at a dose \< 5 mg daily prednisone or bioequivalent per day within 7 days prior to initiation of study drug.
  • Patients requiring adrenal replacement with corticosteroids are eligible if the steroids are at doses ≤ 10 mg prednisone or bioequivalent per day in the absence of active disease.
  • Steroids as premedication for reactions (e.g., CT scan premedication) are allowed.
  • Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent.
  • Prior organ transplantation, including stem cell transplantation.
  • Known history of, or any evidence of active, non-infectious pneumonitis within the last 5 years.
  • Known severe ( v4.03 Grade 3 or 4) infusion-related allergy or acute hypersensitivity reaction attributed to any monoclonal antibody, any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma).
  • Unable tolerate an MRI, or have a to MRI.
  • Active infection requiring systemic therapy.
  • Positive for (HIV) or known acquired immunodeficiency syndrome.
  • Positive test for virus surface antigen (HBV sAg) or virus (HCV antibody) indicating acute or chronic infection.
  • Vaccination within 5 weeks of the first dose of study drug and while on trials is prohibited except for administration of inactivated vaccines.

ATTENTION: Seasonal influenza vaccines for injection are , and are not allowed.

  • (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ NY Heart Association - CC II), or serious cardiac arrhythmia requiring medication.
  • All other unstable, severe, or chronic medical or psychiatric conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis, recent (within the past year) or active suicidal idea in behavior, or laboratory abnormalities that may increase the risk associated with program or judgment of the investigator, would make the patient participation impossible.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

  • BiologicalIpilimumab

    Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses). Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician. This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor.

    Also known as: MDX-010

06

Where to request access

11 sites
  • University "Mother Theresa" Hospital Center; Oncology Department
    Tirana, 1000, Albania
  • University Clinical Center of the Republic of Srpska
    Banja Luka, 78000, Bosnia and Herzegovina
  • Complex Oncology Center
    Plovdiv, 4004, Bulgaria
  • Clinical Hospital Osijek; Dept For Oncology & Radiotherapy
    Osijek, 31000, Croatia
  • Institut of Oncology Al. Trestioreanu Bucharest; Oncology
    Bucharest,, 022338, Romania
  • Regional Oncology Hospital
    Irkutsk, 664035, Russian Federation
  • Rostov Cancer Research Institute
    Rostov-on-Don, 344037, Russian Federation
  • Primorsky Regional Oncology Center
    Vladivostok, 690069, Russian Federation
  • Clinical Hospital Center Bezanijska kosa; Clinic for Oncology
    Belgrade, 11 000, Serbia
  • Inselspital Bern; Medizinische Onkologie
    Bern, 3010, Switzerland
  • Stadtspital Triemli; Frauenklinik
    Zürich, 8063, Switzerland
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT03460782
Lead sponsor
Center Trials & Treatment
Collaborators
BioGene Pharmaceutical Inc.
Responsible party
Sponsor
First posted
Mar 9, 2018
Last update
Nov 8, 2019
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion